Reviva: Announcing Completion of Enrollment of Pivotal Phase 3 Trial
Reviva (NASDAQ: RVPH) is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the US, Europe, and several other countries. Visit https://www.redchip.com/stocks/RVPH to learn more. https://bit.ly/3YAo2Vr
-
1:57
RedChip
1 year agoReviva: Providing a Major Breakthrough for Mental Health and Schizophrenia
8 -
0:18
RedChip
11 months agoReviva: Developing Next-Generation Therapies for Diseases with Significant Unmet Needs
3 -
23:28
Small Caps
1 year agoInvex Therapeutics rolls-out Evolve phase III trial for drug Presendin in IIH patients
12 -
2:00
Asher Press
1 year ago"Pharma Industry Provides 75% of FDA's Drug Review Budget." - Russel Brand
252 -
1:58
Vigilant News Network
1 year agoBrace Yourselves: Pfizer’s RSV Vaccine Approval Signals ‘Something Is Coming’
3.2K15 -
2:07
KGTV
3 years agoINOVIO's Phase 2 clinical trial underway
90 -
1:16
Top Usa NEWS FEEDER
1 year agoFDA Approves New Drug for Early Treatment of Alzheimer’s
27 -
2:20
Waking the World up
1 year agoWhy we NEVER see Failed Clinical Trial Data
3504 -
0:45
JTN2020
1 year agoFDA approves antibody to protect infants from RSV
191 -
1:41
MLordandGod
1 year agoDrs Pressure AstraZeneca To Release Data On Research In Advance Of The Rollout Of Their Covid Jabs
37